130 related articles for article (PubMed ID: 1780697)
21. Evaluation of tumor-associated trypsin inhibitor (TATI) in women with benign and malignant gynecological disease.
Inaudi P; Petrilli S; De Leo V; Bernabei A; Pasqui L; D'Antona N
Scand J Clin Lab Invest Suppl; 1991; 207():11-3. PubMed ID: 1780683
[TBL] [Abstract][Full Text] [Related]
22. Tumour-associated trypsin inhibitor and renal cell carcinoma.
Meria P; Toubert ME; Cussenot O; Bassi S; Janssen T; Desgrandchamps F; Cortesse A; Schlageter MH; Teillac P; Le Duc A
Eur Urol; 1995; 27(3):223-6. PubMed ID: 7601186
[TBL] [Abstract][Full Text] [Related]
23. Tumor-associated trypsin inhibitor (TATI) in bone diseases.
Rapellino M; Pecchio F; Broggi S; Baldi C; Ricardi G; Libertucci D
Scand J Clin Lab Invest Suppl; 1991; 207():65-6. PubMed ID: 1780696
[TBL] [Abstract][Full Text] [Related]
24. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.
Medl M; Ogris E; Peters-Engl C; Leodolter S
Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.
Ychou M; Duffour J; Kramar A; Gourgou S; Grenier J
Dis Markers; 2000; 16(3-4):105-10. PubMed ID: 11381189
[TBL] [Abstract][Full Text] [Related]
26. Value of Combined Detection of Serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the Diagnosis of Gastric Cancer.
Chen C; Chen Q; Zhao Q; Liu M; Guo J
Ann Clin Lab Sci; 2017 May; 47(3):260-263. PubMed ID: 28667025
[TBL] [Abstract][Full Text] [Related]
27. Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma.
Leminen A
Gynecol Oncol; 1990 Dec; 39(3):358-63. PubMed ID: 2258083
[TBL] [Abstract][Full Text] [Related]
28. Tumor-associated trypsin inhibitor in patients with chronic pancreatic diseases.
Plebani M; Basso D; Fabris C; Meggiato T; Del Favero G; Panozzo MP; Fogar P; Faggian D; Angonese C; Burlina A
Klin Wochenschr; 1989 Oct; 67(20):1029-32. PubMed ID: 2586008
[TBL] [Abstract][Full Text] [Related]
29. Biology and function of tumor-associated trypsin inhibitor, TATI.
Stenman UH; Koivunen E; Itkonen O
Scand J Clin Lab Invest Suppl; 1991; 207():5-9. PubMed ID: 1780691
[TBL] [Abstract][Full Text] [Related]
30. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
31. [The clinical information value of an immunoenzyme study of the tumor markers CA-19-9, CEA and AFP in cancer of the stomach, pancreas, colon and rectum].
Ial'chenko NA; Lagutin VD; Lavik NN; Musin II
Vopr Onkol; 1991; 37(9-10):921-4. PubMed ID: 1726842
[TBL] [Abstract][Full Text] [Related]
32. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.
Tocchi A; Costa G; Lepre L; Liotta G; Mazzoni G; Cianetti A; Vannini P
J Cancer Res Clin Oncol; 1998; 124(8):450-5. PubMed ID: 9750022
[TBL] [Abstract][Full Text] [Related]
33. Tumour-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma.
Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
J Cancer Res Clin Oncol; 1994; 120(8):494-7. PubMed ID: 8207049
[TBL] [Abstract][Full Text] [Related]
34. Squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), and tumour-associated trypsin inhibitor (TATI) for monitoring head and neck cancer.
Pectasides D; Bourazanis J; Economides N; Pozadzidou P; Gogou L; Koutsiouba P; Athanassiou A
Int J Biol Markers; 1993; 8(2):81-7. PubMed ID: 8366300
[TBL] [Abstract][Full Text] [Related]
35. Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer.
Yin LK; Sun XQ; Mou DZ
Asian Pac J Cancer Prev; 2015; 16(9):3867-70. PubMed ID: 25987051
[TBL] [Abstract][Full Text] [Related]
36. Concentration of tumor-associated trypsin inhibitor (TATI) in pleural effusions.
Klockars M; Pettersson T; Fröseth B; Selroos O; Stenman UH
Chest; 1990 Nov; 98(5):1159-64. PubMed ID: 2225961
[TBL] [Abstract][Full Text] [Related]
37. The relationship between serum tumor-associated trypsin inhibitor levels and clinicopathological parameters in patients with gastric cancer.
Kemik O; Kemik A; Sümer A; Almali N; Gurluler E; Gures N; Purisa S; Adas G; Dogan Y; Tuzun S
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2923-8. PubMed ID: 24254562
[TBL] [Abstract][Full Text] [Related]
38. Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer.
Pectasides D; Economides N; Bourazanis J; Pozadzizou P; Gogou L; Koutsiouba P; Athanassiou A
Am J Clin Oncol; 1994 Aug; 17(4):307-12. PubMed ID: 8048392
[TBL] [Abstract][Full Text] [Related]
39. Tumor-associated trypsin inhibitor (TATI) in primary esophageal carcinoma.
Gion M; Mione R; Tremolada C; Dalla Palma P; Ruol A; Dittadi R; Leon A; Nosadini A; Castoro C; Bruscagnin G
Scand J Clin Lab Invest Suppl; 1991; 207():37-41. PubMed ID: 1780688
[TBL] [Abstract][Full Text] [Related]
40. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients.
Fioretti P; Gadducci A; Ferdeghini M; Prontera C; Malagnino G; Facchini V; Mariani G; Bianchi R
Gynecol Oncol; 1992 Feb; 44(2):155-60. PubMed ID: 1544592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
